Many studies have indicated that FASN can be used as a biomarker for the diagnosis and prognosis of various cancers, such as triple-negative breast cancer, gastric cancer, and glandular cancer [33,34,35,36,37,38]. The gene discussed is FASN; the disease is triple-negative breast carcinoma.